BNFC September 2025 Update

This update contains 7 significant changes and 2 dose changes

Significant Changes:

• Influenza vaccine: updated guidance for immunisation.
• Influenza vaccine (inactivated): update to ovalbumin content.
• Influenza vaccine (live): update to cautions.
• Respiratory syncytial virus (RSV) vaccine (Abrysvo®): be alert to a small risk of Guillain-Barré syndrome following vaccination in older adults [MHRA/CHM advice].
• Sodium valproate: update to important safety information.
• Valproate (Belvo®, Convulex®, Depakote®, Dyzantil®, Epilim®, Epilim Chrono® or Chronosphere®, Episenta®, Epival®, and Syonell®): updated safety and educational materials to support patient discussion on reproductive risks [MHRA/CHM advice] (advice in sodium valproate, valproic acid; see example in sodium valproate).
• Valproic acid: update to important safety information.

Dose Changes:

• Evinacumab [update to age range].
• Vancomycin [update to indications and dose for neonates].